Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
16.10.2023 - - New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations - - Expanded Collaboration Builds on Vaxcyte’s Current Strategy to Conduct Initial Commercial ... Seite 1